GlassScriptPhysician profile
Jillian Brito
NPI 1497294458
$5,459.24
in general payments reported to CMS, 2019-2025
32 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.30 · 2022: $307 · 2023: $1,326 · 2024: $2,204 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,968 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.12 |
| Education | $165.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $947.83 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $753.80 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $568.96 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $445.67 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $443.53 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $398.54 | 2022-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $355.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $271.10 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $151.73 | 2024-2025 | Livdelzi |
| Aimmune Therapeutics, INC. | $148.79 | 2024 | |
| Intercept Pharmaceuticals, INC. | $120.30 | 2023-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $109.70 | 2023-2024 | Linzess |
| Exact Sciences Corporation | $81.87 | 2023-2024 | Cologuard Collection Kit |
| Genzyme Corporation | $74.48 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $71.96 | 2024-2025 | Iqirvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $64.46 | 2023-2025 | Sutab, Suflave |
| Novo Nordisk INC | $55.02 | 2025 | Wegovy |
| Evoke Pharma, INC. | $54.29 | 2023-2024 | Gimoti |
| Redhill Biopharma INC. | $49.71 | 2022-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $38.39 | 2024 | Dupixent |
| Mirum Pharmaceuticals, INC. | $33.84 | 2025 | Livmarli |
| Boston Scientific Corporation | $33.65 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Lilly USA, LLC | $25.36 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.89 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $21.78 | 2023 | Kristalose |
| Phadia US INC. | $19.30 | 2021 | |
| Pfizer INC. | $17.66 | 2023 | |
| Merck Sharp & Dohme LLC | $17.60 | 2022 | |
| Vivus LLC | $17.05 | 2025 | Pancreaze |
| Fresenius Kabi USA, LLC | $15.97 | 2023 | |
| Axonics, INC. | $14.96 | 2023 | Axonics |
| Nestle Healthcare Nutrition INC. | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Brito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.